HEREDITARY ANGIOEDEMA MARKET ANALYSIS

Hereditary Angioedema Market is segmented By Type (Hereditary Angioedema Type I and Hereditary Angioedema Type II), By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 3, 2024, KalVista Pharmaceuticals, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration had accepted its New Drug Application (NDA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for the on-demand treatment of HAE attacks in patients aged 12 years and older
On June 18, 2024, Ionis Pharmaceuticals, Inc., a pharmaceutical company, announced a licensing agreement with Otsuka Pharmaceutical Co., Ltd., a biopharmaceutical company, for granting Otsuka Pharmaceutical Co., Ltd. the exclusive rights to donidalorsen across the Asia Pacific region. Donidalorsen is an investigational RNA-targeted prophylactic treatment for HAE. This agreement expands their collaboration, allowing Otsuka to pursue regulatory approvals and commercialization in this key market
On June 18, 2024, KalVista Pharmaceuticals, Inc., a pharmaceutical company, announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is designed for the on-demand treatment of HAE) attacks in adult and pediatric patients aged 12 years and older